Kirr Marbach & Co. LLC IN Reduces Position in ICU Medical, Inc. (NASDAQ:ICUI)

Kirr Marbach & Co. LLC IN lowered its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 6.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 21,919 shares of the medical instruments supplier’s stock after selling 1,616 shares during the quarter. Kirr Marbach & Co. LLC IN’s holdings in ICU Medical were worth $3,401,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the company. Hexagon Capital Partners LLC boosted its position in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares during the last quarter. Allworth Financial LP lifted its stake in shares of ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the period. Venturi Wealth Management LLC boosted its holdings in ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in ICU Medical during the second quarter valued at $70,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of ICU Medical in the third quarter worth about $72,000. 96.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ICUI has been the subject of several recent analyst reports. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. KeyCorp boosted their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Finally, Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and an average price target of $199.67.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,973,261.12. This trade represents a 10.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 972 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the transaction, the director now directly owns 5,037 shares in the company, valued at $796,400.07. The trade was a 16.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,737 shares of company stock valued at $4,941,832. 6.70% of the stock is owned by company insiders.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $169.87 on Wednesday. ICU Medical, Inc. has a 52-week low of $86.80 and a 52-week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The business has a fifty day moving average of $161.11 and a two-hundred day moving average of $161.73.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.